Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM - Research Report) yesterday and set a price target of $25.00. The company's shares opened today at $6.03.McCarthy covers the Healthcare sector, focusing on stocks such as Atossa Therapeutics, Capricor Therapeutics, and VistaGen Therapeutics. According to TipRanks, McCarthy has an average return of -36.4% and a 19.32% success rate on recommended stocks. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Actinium Pharmaceuticals with a $35.00 average price target, a 480.43% upside from current levels. In a report released yesterday, H.C.
https://www.tipranks.com/news/blurbs/maxim-group-sticks-to-their-buy-rating-for-actinium-pharmaceuticals-atnm?utm_source=advfn.com&utm_medium=referral
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Nov 2022 à Déc 2022 Plus de graphiques de la Bourse Actinium Pharmaceuticals
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Déc 2021 à Déc 2022 Plus de graphiques de la Bourse Actinium Pharmaceuticals